On March 18, 2026 Leveragen, a Boston-based biotechnology company developing next-generation in vivo platforms for antibody discovery, reported a collaboration agreement with Daiichi Sankyo (TSE: 4568) to support research efforts in advanced biologics.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the collaboration, Daiichi Sankyo will work with Leveragen to apply Leveragen’s in vivo antibody discovery capabilities in support of selected research programs. The collaboration reflects a shared interest in exploring innovative discovery approaches that may enable the generation and evaluation of antibody-based biologics across multiple therapeutic areas.

"We are pleased to collaborate with Daiichi Sankyo, a global leader in antibody therapeutics with deep scientific expertise and a strong commitment to innovation," said Dr. Weisheng Chen, Founder and Chief Executive Officer of Leveragen. "This collaboration reflects growing interest in next-generation in vivo discovery platforms and their potential to support diverse biologic research efforts. We look forward to working together to advance new discovery programs."

The collaboration further supports Leveragen’s strategy of working with leading pharmaceutical and biotechnology companies to apply its in vivo discovery platforms in early-stage research and preclinical development.

(Press release, Leveragen, MAR 18, 2026, https://www.businesswire.com/news/home/20260318034240/en/Leveragen-Announces-Collaboration-with-Daiichi-Sankyo-to-Support-Development-of-Advanced-Biologics-Using-Next-Gen-In-Vivo-Antibody-Discovery-Platforms [SID1234663720])